Skip to content
Study details
Enrolling now

IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors

M.D. Anderson Cancer Center
NCT IDNCT05039801ClinicalTrials.gov data as of Apr 2026
Phase

Phase 1

Target enrollment

54

Study length

about 4.7 years

Ages

18+

Locations

1 site in TX

What this study is about

This trial is testing a treatment called IACS-6274, possibly with bevacizumab and paclitaxel, to see if it's safe and tolerable in people with advanced solid tumors. The goal is to find the highest dose that can be given safely.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Receive Bevacizumab
  • 2.Take Capivasertib
  • 3.Take Glutaminase-1 Inhibitor IACS-6274
  • +1 more

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Injection / IVOral

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Drug classes

bevacizumab, capivasertib, paclitaxel (Taxane chemotherapy; stabilizes microtubules)

Drug routes

infusion, oral (Oral Tablet), injection, intravenous

Endpoints

Primary: Incidence of adverse events (AEs)

Body systems

Oncology